Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy
Published: 14 February 2019| Version 1 | DOI: 10.17632/x5xyn9bz38.1
Supplement 2. Major clinicopathological characteristics of 99 patients with uncommon EGFR mutation.
National Institute of Clinical Excellence